BVS Bioventus

Bioventus Agrees to Nationwide Contract with Cigna Commercial Plans for DUROLANE® and GELSYN-3® for Knee Osteoarthritis

Bioventus Agrees to Nationwide Contract with Cigna Commercial Plans for DUROLANE® and GELSYN-3® for Knee Osteoarthritis

DURHAM, N.C., May 02, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has agreed to a nationwide contract with Cigna® commercial plans. Beginning July 1, 2022, Cigna® commercial plan members will have access to both  and , to treat knee osteoarthritis (OA) pain. DUROLANE, is a single-injection and GELSYN-3, is a three-injection hyaluronic acid (HA)-based joint-fluid treatment for patients. Durolane will be exclusive to all Cigna patients while Gelsyn-3 will be one of two multi-injection HA products under contract.

OA involves the breakdown, or degeneration, of cartilage and the synovial fluid that cushions and lubricates joint tissues. Injection treatments of HA-based products, such as DUROLANE and GELSYN-3, help manage knee OA pain.

“We are pleased and excited DUROLANE and GELSYN-3 are among the preferred options available to Cigna® members and physicians,” said Tim Donovan, Vice President of Market Access & Health Economics for Bioventus. “Both now have access to two safe HA products that are proven to provide relief from knee OA pain.”

About Bioventus

Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for pain treatment, restorative therapies and surgical solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit , and follow the Company on and . Bioventus, the Bioventus logo, GELSYN-3 and DUROLANE are registered trademarks of Bioventus LLC.

Media Contact:

Jamica Whitaker

Bioventus

919-666-5770

Investor Inquiries:

Dave Crawford

Bioventus

919-474-6787



EN
02/05/2022

Underlying

BVSBioventus

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bioventus

 PRESS RELEASE
Free
BVS BIOVENTUS

Bioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Resul...

Bioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Results on March 5, 2026 DURHAM, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- , a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2025 before the market opens on Thursday, March 5, 2026. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call....

February 24, 2026 1 EN
 PRESS RELEASE
Free
BVS BIOVENTUS

Bioventus to Present at the 44th Annual J.P. Morgan Healthcare Confere...

Bioventus to Present at the 44th Annual J.P. Morgan Healthcare Conference DURHAM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 9:45 a.m. PT (12:45 p.m. ET). The live webcast of the presentation, including Q&A, may be accessed on the Investors section of the Bioventus website and will be available for replay until February 14, 2026. About BioventusBioventus delivers c...

January 6, 2026 1 EN
 PRESS RELEASE
Free
BVS BIOVENTUS

Bioventus to Present at the Piper Sandler 37th Annual Healthcare Confe...

Bioventus to Present at the Piper Sandler 37th Annual Healthcare Conference DURHAM, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Executive Officer, will present at the Piper Sandler Healthcare Conference on Wednesday, December 3, 2025, at 10:10 a.m. ET. A live webcast of the presentation, followed by a question-and-answer session will be available on the “Investors” section of the Company’s website at and will be available for replay on that site following the ...

November 25, 2025 1 EN
 PRESS RELEASE
Free
BVS BIOVENTUS

Bioventus Reports Third Quarter Financial Results

Bioventus Reports Third Quarter Financial Results Q3 reported revenue of $138.7 million was comparable to last year and organic* revenue advanced 8%Third quarter GAAP earnings of $0.05 per diluted share increased compared to the prior-year period loss of $0.08 per diluted shareNon-GAAP earnings* of $0.15 per diluted share increased 200%Cash from operations of $30.1 million increased 192%Company reaffirms revenue, Adjusted EBITDA* and Non-GAAP EPS* guidance for full year 2025 DURHAM, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) --  Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a ...

November 4, 2025 1 EN
 PRESS RELEASE
Free
BVS BIOVENTUS

Bioventus to Report Third Quarter of Fiscal Year 2025 Financial Result...

Bioventus to Report Third Quarter of Fiscal Year 2025 Financial Results on November 4, 2025 DURHAM, N.C., Oct. 28, 2025 (GLOBE NEWSWIRE) -- a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2025 before the market opens on Tuesday, November 4, 2025. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Cal...

October 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch